In Depth 2 Dec 2024
The rise of cancer vaccines: A new era in immunotherapy
Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight tumors.
Peptides
- Latest Posts
Best in Biotech 14 Oct 2024
Six biomimicry biotech companies harnessing nature’s wisdom to develop breakthrough drug candidates
Find out more about six biomimicry companies harnessing nature’s wisdom to create drug candidates for the benefit of human health.
In Depth 7 Oct 2024
Spinal cord injury: Are we getting closer to a treatment?
Delve into the spinal cord injury treatment landscape with a few pharmaceutical approaches that could tackle this complex condition.
Sublingual delivery: the future for GLP-1 receptor agonists
Discover how GLP-1 receptor agonists, now thriving in obesity treatment, could benefit from a more patient-friendly sublingual delivery method.
In Depth 25 Sep 2024
How Pfizer’s decision in the ’90s cost them a stronghold in the GLP-1 market
Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ’90s.
Best in Biotech 5 Sep 2024
Six biotech companies that could revolutionize obesity treatments
In this article, we take a look at six biotechs focused on bringing drugs to treat obesity to the market.
ADVERTISEMENT
ADVERTISEMENT
News and Trends 28 Aug 2024
GLP-1 shortage: Can biotech companies keep up with rising demand?
How is the biotech industry responding to the GLP-1 drug shortage? We asked experts in the field to answer this question.
How a microbial expression update is driving biotech innovation
Discover how microbial expression systems are revolutionizing protein production for next-gen therapies like antibodies and peptides.
In Depth 25 Mar 2024
Beyond Wegovy: Could Novo Nordisk’s new experimental weight loss pill be even better?
Discover how Novo Nordisk’s new experimental obesity pill, amycretin, could be even more efficient for weight loss than Wegovy.
In Depth 4 Jan 2024
Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases?
Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.
In Depth 30 Nov 2023
Could an Alzheimer’s vaccine make treatment more affordable?
Alzheimer’s research has come a long way since the disease was first identified more than a century ago. Now, as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic? […]
In Depth 22 Nov 2023
Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment
Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […]
ADVERTISEMENT
